Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 1966 • 2018 ACR/ARHP Annual Meeting
Transcriptome and Methylome Integrative Molecular Analysis Uncovers a New Systemic Autoimmune Disease Classification
Guillermo Barturen¹, Sepideh Babaei², Francesc Catala-Moll³, Zuzanna Makowska², Antonio García-Gómez³, Anne Buttgereit⁴, Elena Carnero-Montoro¹, Sikander Hayat⁴, Martin Kerick⁵, Thomas Charlon⁶, David C Gemperline⁷, Lucas Le Lann⁸, Rosa Quirantes-PIné⁹, Isabel Borrás-Linares¹⁰, Brian Muchmore¹, Jorge Kageyama⁴, Javier Rodríguez-Ubreva³, Alvaro Fernández-Ochoa⁹, Pedro Carmona Sanz¹¹, Christophe Jamin⁸, Ralf Lesche², Robert J. Benschop⁷, Chris Chamberlain¹², Ernst R. Dow⁷, Tania Gomes¹, Maria Juárez¹³, Laurence Laigle¹⁴, Jacqueline Marovac¹², Fiona MacDonald¹⁵, Jerome Wojcik⁶, Esteban Ballestar¹⁶, Lorenzo Beretta¹⁷, Maria Orietta Borghi¹⁸, Johan Frostegård¹⁹, Maria Luisa Garcia²⁰, Javier Martín⁵, Jacques-Olivier Pers⁸, Yves Renadineau²¹, Antonio Segura Carretero⁹ and Marta Alarcón-Riquelme^1,19, ¹Medical Genomics, Center for Genomics and Oncological Research (GENYO), Granada, Spain, ²Pharmaceuticals Division, Bayer Pharma Aktiengesellschaft, Berlin, Germany, ³Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain, ⁴Bayer Pharma Aktiengesellschaft, Berlin, Germany, ⁵Institute of Parasitology and Biomedicine López Neyra, Spanish National Research Council, Granada, Spain, ⁶QuartzBIO, SA, Geneva, Switzerland, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸U1227, Université de Brest, Inserm, Labex IGO, CHU de Brest, Brest, France, ⁹Department of Analytical Chemistry, University of Granada, Granada, Spain, ¹⁰Analytical Chemistry, University of Granada, Granada, Spain, ¹¹Unit of Bioinformatics, Center for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Granada, Spain, ¹²UCB Pharma, Slough, United Kingdom, ¹³UCB, Slough, United Kingdom, ¹⁴Institut de Recherches Internationales Servier, Suresnes, France, ¹⁵Bayer Pharma G, Berlin, Germany, ¹⁶Cancer Epigenetics and Biology Programme (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain, ¹⁷Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ¹⁸University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy, ¹⁹Unit for Chronic Inflammatory Diseases, Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ²⁰Nano-Imaging, BIONAND. Centro Andaluz de Nanotecnología y Biomedicina, Malaga, Spain, ²¹U1227, Université de Brest, inserm, Labex IGO, CHU de brest, Brest, France
Background/Purpose: Systemic autoimmune diseases (SADs) are chronic inflammatory conditions with autoimmune aetiology and many common clinical features, difficulting diagnosis and adequate treatment decisions. Finding new…
Abstract Number: 2542 • 2018 ACR/ARHP Annual Meeting
Integrated Exposure-Response Analyses for Upadacitinib Efficacy and Effects on Laboratory Parameters in Rheumatoid Arthritis – Analyses of Phase 2b Studies
Mohamed-Eslam Mohamed¹, Insa Winzenborg², Eva Doelger², Peter Noertersheuser³, Heidi S. Camp¹, Sebastian Meerwein³ and Ahmed A. Othman¹, ¹AbbVie Inc., North Chicago, IL, ²AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany, ³AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Upadacitinib is an oral, selective inhibitor of Janus kinase 1 (JAK1) which is currently being evaluated for the treatment of several autoimmune disorders, including…
Abstract Number: 424 • 2017 ACR/ARHP Annual Meeting
Re-Establishment of Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, in Rheumatoid Arthritis Patients after Temporary Discontinuation
Jeffrey Kaine¹, John Tesser², Ryan DeMasi³, Liza Takiya³, Lisy Wang⁴, Mark Snyder³, Haiyun Fan⁴ and Jürgen Wollenhaupt⁵, ¹Sarasota Arthritis Research Center, Sarasota, FL, ²Arizona Arthritis & Rheumatology Associates, Glendale, AZ, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT, ⁵Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We assessed tofacitinib efficacy and safety after temporary discontinuation and…
Abstract Number: 902 • 2017 ACR/ARHP Annual Meeting
Evidence for Inhibition of Osteoclastogenesis By Cytomegalovirus Infection: Implication in RA Bone Erosion and Identification of a Cellular Protein As a Therapeutic Target
Benjamin Rauwel¹, Michel Baron¹, Adeline Ruyssen-Witrand², Delphine Nigon³, Yannick Degboé², Jacques Izopet¹, Alain Cantagrel¹ and Jean-Luc Davignon¹, ¹CPTP, INSERM UMR 1043, Toulouse, France, ²Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ³Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France
Background/Purpose: Exacerbated differentiation of monocytes into osteoclasts (OC) contributes to the pathogenesis of rheumatoid arthritis (RA) resulting in severe bone erosion and functional damage. Osteoclastogenesis…
Abstract Number: 2013 • 2017 ACR/ARHP Annual Meeting
Physician Experience and Patient´s Disease Activity Affect the Impact of Musculoskeletal Ultrasound on the Treatment Decision in Rheumatoid Arthritis Patients
César Sifuentes-Cantú¹, Irazu Contreras-Yañez², Marwin Gutierrez³ and Virginia Pascual-Ramos⁴, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ³Rheumatology, Instituto Nacional de Rehabilitación, Mexico City, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: In a real clinical setting of RA outpatients, we previously showed that musculoskeletal ultrasound (MUS) added to clinical evaluation impacted the treatment decision in…
Abstract Number: 2796 • 2017 ACR/ARHP Annual Meeting
A Randomized, Double Blind Trial over 52 Weeks to Demonstrate Bioequivalence of GP2013 and Reference Rituximab in Patients with Rheumatoid Arthritis
Josef S. Smolen¹, Stanley B Cohen², Morton Scheinberg³, Tamas Shisha⁴, Dmitrij Kollins⁴, Peijuan Zhu⁵, Liyi Cen⁴, Alan J. Kivitz⁶, Andra Rodica Balanescu⁷, Juan J. Gomez-Reino⁸ and Hans-Peter Tony⁹, ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²Metroplex Clinical Research Centre, Dallas, TX, ³Rheumatology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil, ⁴Clinical Development, Sandoz, a Novartis Division, Holzkirchen, Germany, ⁵Clinical Pharmacology, Sandoz, a Novartis Division, NJ, NJ, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Research Center of Rheumatic Diseases, “Sf. Maria” Hospital, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, ⁸BIOBADASER, Santiago, Spain, Santiago de Compostela, Spain, ⁹Department of Internal Medicine 2, Rheumatology and Clinical Immunology, University Hospital Würzburg, Würzburg, Germany
Background/Purpose: Rituximab (RTX) is a mAB indicated for the treatment of RA in patients with inadequate response to anti-TNF therapy. The current study compares the…
Abstract Number: 428 • 2017 ACR/ARHP Annual Meeting
Impact of Smoking Cessstion Advise in Patients with Rheumatoid Arthritis to Help Quit Smoking
Shama Khan¹, Ahmad Butt¹, Emmett Brennan², Ausaf Mohammad¹ and Killian O Rourke³, ¹Rheumatology, Midlands Regional Hospital, Tullamore, Ireland, ²Tullamore, Midlands Regional Hospital, Tullamore, Ireland, ³Rheumatology, Midlands Regional Hospital, Tullamore, Co Offaly, Ireland
Background/Purpose: Smoking is associated with an increased risk of comorbidities in rheumatoid arthritis (RA) and may reduce the efficacy of anti-rheumatic therapies. Smoking cessation is…
Abstract Number: 1055 • 2017 ACR/ARHP Annual Meeting
A Combination of Self-Reported Symptoms and ACPA Testing Can Identify Individuals with Previously Undiagnosed Inflammatory Arthritis in a Health-Fair Setting
Elizabeth A. Bemis¹, Nicholas Ellinwood², Kaylynn Aiona³, Christopher C. Striebich⁴ and Kevin D. Deane⁵, ¹Epidemiology, Colorado School of Public Health, Aurora, CO, ²Pharmacology and Toxicology Graduate Group, University of California Davis, Davis, CA, ³Denver Health and Hospitals and Colorado School of Public Health, Denver, CO, ⁴Division of Rhuematology, University of Colorado School of Medicine, Aurora, CO, ⁵Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Early identification and treatment of inflammatory arthritis (IA) and in particular rheumatoid arthritis (RA) can lead to improved outcomes. However, there are often delays…
Abstract Number: 2239 • 2017 ACR/ARHP Annual Meeting
The Recall Program: Data from a Multicenter Educational Event on Patients with Rheumatoid Arthritis
Andrea Delle Sedie¹, Emilio Filippucci², Oscar Epis³, Pierluigi Macchioni⁴, Sebastiano Tropea⁵, Carlo Bonali⁶, Marco Canzoni⁷ and Annamaria Iagnocco⁸, ¹Department Rheumatology, University of Pisa, Pisa, Italy, ²Rheumatology Unit, Università Politecnica delle Marche, Jesi, Italy, ³Rheumatology Unit, Ospedale Niguarda, Milano, Italy, ⁴Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, ⁵ASP7, Busacca Hospital, Ragusa, Italy, ⁶Rheumatology Unit,, Ospedale San Paolo, Bari, Italy, ⁷Local Health Unit (ASL) Rome 1, Rome, Italy, ⁸Academic Rheumatology Unit, Università degli Studi di Torino, Torino, Italy
Background/Purpose: ultrasound (US) is able to show subclinical synovitis in patients (pts) with rheumatoid arthritis (RA) who are in clinical remission (CR); this has been…
Abstract Number: 2827 • 2017 ACR/ARHP Annual Meeting
A Novel Statistical Method to Resolve Cellular Heterogeneity in Disease Tissues: Integrating Transcriptomic Data in Accelerating Medicines Partnership (AMP) – RA Network Phase 1 Data
Fan Zhang¹, Kamil Slowikowski², Chamith Fonseka¹, Kevin Wei³, Maria Gutierrez-Arcelus⁴, James Lederer⁵, Nir Hacohen⁶, Vivian P. Bykerk⁷, Michael Holers⁸, Peter Gregersen⁹, Mandy J. McGeachy¹⁰, Larry W. Moreland¹¹, Andrew Filer¹², Costantino Pitzalis¹³, Yvonne C. Lee¹⁴, Jennifer H. Anolik¹⁵, Michael Brenner⁴ and Soumya Raychaudhuri¹⁶, ¹Divisions of Genetics and Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical Schoo, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Harvard Medical School, Boston, MA, ⁷2-005, Mt Sinai Hospital, Toronto, ON, Canada, ⁸Medicine, Division of Rheumatology, University of Colorado Denver, Aurora, CO, ⁹The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, ¹⁰Medicine, University of Pittsburgh, Pittsburgh, PA, ¹¹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹²Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom, ¹³Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ¹⁴Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁵Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ¹⁶Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Detecting distinct cellular subsets in disease tissues is key to understanding the pathogenesis of immune diseases, for example in synovial tissues in rheumatoid arthritis…
Abstract Number: 430 • 2017 ACR/ARHP Annual Meeting
Implementation of a Treat-to-Target Remission Strategy for Rheumatoid Arthritis in Australian Public and Private Rheumatology Clinics – Identification of Clinician and Patient Barriers
Helen Benham¹, Hedva Chiu², Joanne Tesiram³, Peter Landsberg⁴, Andrew A. Harrison⁵, Peter Nash⁶, Ranjeny Thomas⁷ and Mieke van Driel⁸, ¹The University of Queensland Faculty of Medicine, Brisbane, Australia, ²The University of Queensland Faculty of Medicine, Woolloongabba, Australia, ³Rheumatology, Princess Alexandra Hospital, Woolloongabba, Australia, ⁴Princess Alexandra Hospital, Woolloongabba, Australia, ⁵Department of Medicine, University of Otago Wellington, Wellington, New Zealand, ⁶University of Queensland, Brisbane, Australia, ⁷Diamantina Institute, Diamantina Institute University of Queensland, Brisbane, Australia, ⁸Primary Care Clinical Unit, The University of Queensland Faculty of Medicine, Herston, Australia
Background/Purpose: Treat-to-target in rheumatoid arthritis (RA-T2T) improves outcomes for people living with RA. Implementing T2T in routine clinical practice however presents many challenges and an…
Abstract Number: 1087 • 2017 ACR/ARHP Annual Meeting
Rheumatology Clinic Smoking Cessation Protocol Markedly Increases Quit Line Referrals
Christie M. Bartels¹, Edmond Ramly², Daniel Panyard³, Diane Lauver⁴, Heather Johnson⁵, Zhanhai Li⁶, Emmanuel Sampene⁷, Megan Piper⁸ and Patrick McBride⁵, ¹Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI, ²Industrial and Systems Engineering, University of Wisconsin College of Engineering, Madison, WI, ³Population Health, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴University of Wisconsin-Madison School of Nursing, Madison, WI, ⁵Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁷Biostatistics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁸University of Wisconsin Center for Tobacco Research and Intervention, Madison, WI
Background/Purpose: Smoking predicts higher incidence, greater severity, and reduced treatment responses in rheumatoid arthritis, lupus, and spondyloarthritis. However, cessation advice and quit line referral occur…
Abstract Number: 2261 • 2017 ACR/ARHP Annual Meeting
Supporting Smoking Cessation in RA and SLE: Identifying Patient-Centered Outcomes
Aimée Wattiaux¹, Laura Block², Andrea Gilmore-Bykovskyi², Edmond Ramly³, Jane Sadusky⁴, Megan Piper⁵, Brittany Bettendorf⁶, Ann Rosenthal⁷ and Christie M. Bartels⁸, ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin School of Nursing, Madison, WI, ³Industrial and Systems Engineering, University of Wisconsin College of Engineering, Madison, WI, ⁴Research Consultant, Madison, WI, ⁵University of Wisconsin Center for Tobacco Research and Intervention, Madison, WI, ⁶Rheumatology, Medical College of Wisconsin, MIlwaukee, WI, ⁷Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁸Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI
Background/Purpose: Patients with RA and SLE are at higher risk for premature cardiovascular disease (CVD) than peers. Smoking is a leading modifiable risk factor for…
Abstract Number: 2938 • 2017 ACR/ARHP Annual Meeting
Is Synovial Hypertrophy without Doppler Activity in Rheumatoid Arthritis Joints Sensitive to Change ? – Results of a Longitudinal Ultrasound Study
Lene Terslev¹, Mikkel Østergaard¹, Joseph Sexton² and Hilde B Hammer², ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Ultrasound (US) is used to assess diseases activity in rheumatoid arthritis (RA). Gray scale (GS) US shows the synovial hypertrophy (SH) and Doppler the…
Abstract Number: 456 • 2017 ACR/ARHP Annual Meeting
Time from First Symptom Onset to First Advanced Therapy Amongst RA Patients in Latin America
Ivanio Pereira¹, Valderilio F Azevedo², Wilson Bautista-Molano³, Julio Casasola⁴, Generoso Guerra⁵, David Vega-Morales⁶, Enrique R Soriano⁷, Diana Rocio Gil⁸, José Antonio Maldonado-Cocco⁹, Leandro Aldunate¹⁰ and Steve Lobosco¹¹, ¹Rheumatology, Universidade Federal de Santa Catarina, Hospital Universitário, Divisão de Reumatologia.Brazil, Florianopolis, Brazil, ²Adjunct Professor of Rheumatology, Federal University of Paraná; Brazil, Curitiba, Brazil, ³School of Medicine, Universidad Militar Nueva Granada and Rheumatology Department Hospital Militar. Colombia, Bogotá, Colombia, ⁴Rheumatology, Hospital General de Mexico, Mexico, Mexico, ⁵Centro Médico Paitilla Internal Medicine and Rheumatology Department. Panama, Panama City, Panama, ⁶Universidad Autónoma de Nuevo León. Rheumatology Service, Internal Medicine Department, Hospital Universitario "Dr. José Eleuterio González". Mexico, Monterrey, Mexico, ⁷Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸ART Medica - Hospital Universitario Mayor MEDERI Internal Medicine and Rheumatology. Colombia., Bogota, Colombia, ⁹Buenos Aires University, Consulting Professor of Rheumatology, Buenos Aires University. Argentina, Buenos Aires, Argentina, ¹⁰Immunology, Janssen Latin America, Buenos Aires, Argentina, ¹¹Adelphi, Immunology Director- Adelphi Group, Manchester, United Kingdom
Background/Purpose: To understand the RA patient pathway in Latin America from first symptom onset; including time to diagnosis and to first advanced treatment. Methods: Data…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].